De­spite bruis­ing mar­ket, two biotechs price their IPOs while an­oth­er launch­es its Nas­daq bid

The cur­rent mar­ket sit­u­a­tion for biotechs is cer­tain­ly not ide­al, but that is not de­ter­ring a few com­pa­nies from div­ing in­to the wa­ters of Wall Street.

Two com­pa­nies, Boston-based Hill­e­Vax and San Diego-based Be­lite Bio, will make their Nas­daq de­buts Fri­day, while an­oth­er biotech that has some fa­mil­iar names at­tached filed for an IPO.

Af­ter fil­ing ear­li­er this month Hill­e­Vax grabs more than $150M

Hill­e­Vax, a norovirus vac­cine de­vel­op­er spun out from Take­da by late biotech leg­end Tachi Ya­ma­da, went pub­lic on the back of a $150 mil­lion-plus de­but and priced its IPO at $17 per share.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.